Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Asian Journal of Psychiatry

• Publication date

  2014-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.ajp.2013.12.010PMID 24813033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Understanding And Treating Tardive Dyskinesia

  2016cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

  2010cited by this paper
• A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.

  2010cited by this paper
• The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.

  2009influential reference
• Non‐therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: A meta‐analysis

  2009cited by this paper
• Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

  2008cited by this paper
• Five‐year follow‐up during antipsychotic treatment: efficacy, safety, functional and social outcome

  2007cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• Increased risk of extrapyramidal side‐effect treatment associated with atypical antipsychotic polytherapy

  2006cited by this paper
• Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.

  2005influential reference
• Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study

  2005cited by this paper
• A prospective study of tardive dyskinesia in Japan

  2005cited by this paper
• Antipsychotic Medications and Drug‐Induced Movement Disorders Other Than Parkinsonism: A Population‐Based Cohort Study in Older Adults

  2005cited by this paper
• Tardive dyskinesia in non-western countries: A review

  2005influential reference
• Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005influential reference
• Contents of The American Journal of Psychiatry

  2004cited by this paper
• Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

  2004cited by this paper
• Clinical and familial correlates of tardive dyskinesia in India and Israel.

  2004cited by this paper
• Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.

  2004cited by this paper
• Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.

  2004cited by this paper
• Chlorpromazine equivalent doses for the newer atypical antipsychotics.

  2003cited by this paper
• Tardive dyskinesia in Chinese inpatients with chronic schizophrenia.

  2003influential reference
• Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review.

  2002influential reference
• A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

  2002cited by this paper
• Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

  1999cited by this paper
• Conventional vs. newer antipsychotics in elderly patients.

  1999cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.

  1998cited by this paper
• Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications

  1997cited by this paper
• Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.

  1997cited by this paper
• RISK FACTORS FOR TARDIVE DYSKINESIA

  1994influential reference
• Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

  1993cited by this paper
• Tardive dyskinesia.

  1993cited by this paper
• A 10‐year follow‐up study of tardive dyskinesia

  1992cited by this paper
• Prospective study of tardive dyskinesia incidence in the elderly.

  1991cited by this paper
• Tardive dyskinesia: prevalence, incidence, and risk factors.

  1988cited by this paper
• Integrating incidence and prevalence of tardive dyskinesia.

  1986influential reference
• An international survey of tardive dyskinesia

  1985cited by this paper
• Tardive dyskinesia: prevalence, incidence, and risk factors.

  1985cited by this paper
• Effect of Anticholinergics on Tardive Dyskinesia

  1984cited by this paper
• Recent trend on the prevalence of tardive dyskinesia in Japan.

  1984cited by this paper
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• Tardive Dyskinesia in India: A Prevalence Study

  1982influential reference
• Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics.

  1982cited by this paper
• Tardive dyskinesia: prevalence and risk factors, 1959 to 1979

  1982cited by this paper
• Changes in prevalence, severity, and recovery in tardive dyskinesia with age.

  1980cited by this paper
• A rating scale for tardive dyskinesia

  1979cited by this paper
• The pharmacology of tardive dyskinesias.

  1973cited by this paper
• STATISTICAL METHODS

  1967cited by this paper

• A novel ratiometric electrochemical sensor based on bifunctional copper-coordinated polydopamine molecular imprinting for the detection of chlorpromazine

  2025cites this paper
• Tardive Syndromes: A Challenging Multitude of Maladies

  2025cites this paper
• Tardive dyskinesia in Asia— current clinical practice and the role of neurologists in the care pathway

  2024cites this paper
• Movement Disorders in Migrants

  2022cites this paper
• Drug-Induced Tardive Dyskinesia

  2021cites this paper
• Assesment of Risk Factors for Tardive Dyskinesia.

  2020cites this paper
• Time for a New Slate in Tardive Dyskinesia Research

  2020cites this paper
• A Focused Update on Tardive Dyskinesia

  2020cites this paper
• Recent Advances in the Pharmacology of Tardive Dyskinesia

  2020cites this paper
• Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia

  2020cites this paper
• Continuous versus extended antipsychotic dosing in schizophrenia: Less is more.

  2020cites this paper
• Unusual Phenomenologies

  2020cites this paper
• CPAA_A_285585 179..187

  2020cites this paper
• Prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital, psychiatric clinic, Ethiopia: Institution based a cross-sectional study CURRENT STATUS:

  2020influential citation
• The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders

  2019cites this paper
• Prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital, psychiatric clinic, Ethiopia: Institution based a cross-sectional study

  2019influential citation
• Clinical risk factors for the development of tardive dyskinesia.

  2018cites this paper
• Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

  2018cites this paper
• Frequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorder.

  2018cites this paper
• Lipoic acid and haloperidol‐induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia

  2017cites this paper
• Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.

  2017cites this paper
• Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

  2017cites this paper
• Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

  2015cites this paper